论文部分内容阅读
已知淋巴细胞与白细胞介素(IL-2)一起培养1～2周,可诱导出有杀伤活性的细胞,即淋巴因子激活的杀伤(LAK)细胞。从癌症患者采取淋巴细胞进行培养,将诱导的LAK 细胞再回输给患者,可使病灶缩小,此种方法被称为LAK 疗法。LAK 疗法与输血医学关系密切。输血中通过血液成分的采取技术,使采取大量淋巴细胞变得容易。并且,LAK 疗法与自家骨髓移植和自家输血的概念亦相近,如果没有采取淋巴细胞的技术和输血知识,就不能可靠地实施本疗法,为使其常规化和迅速发展,下述问题有待进一步研究。
It is known that lymphocytes are incubated with interleukin (IL-2) for 1 to 2 weeks to induce killer cells, lymphokine-activated killer (LAK) cells. The use of lymphocytes from cancer patients for culture and the return of induced LAK cells to patients can reduce the size of the lesions. This method is called LAK therapy. LAK therapy is closely related to transfusion medicine. The technique of taking blood components through blood transfusions makes it easier to take large numbers of lymphocytes. In addition, the concept of LAK therapy is similar to that of bone marrow transplantation and home blood transfusion. If lymphocyte technology and blood transfusion knowledge are not used, this therapy cannot be reliably implemented. To make it regular and rapid, the following problems need further study. .